57132-40-8

Basic information

• Product Name: 3-[2-(4'-bromophenyl)-2-oxoethyl]-4-methylthiazolium bromide
• Synonyms: 3-[2-(4'-bromophenyl)-2-oxoethyl]-4-methylthiazolium bromide
• CAS NO: 57132-40-8
• Molecular Weight: 377.099
• Mol File: 57132-40-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-[2-(4'-bromophenyl)-2-oxoethyl]-4-methylthiazolium bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[2-(4'-bromophenyl)-2-oxoethyl]-4-methylthiazolium bromide(57132-40-8)
• EPA Substance Registry System: 3-[2-(4'-bromophenyl)-2-oxoethyl]-4-methylthiazolium bromide(57132-40-8)

Safety Data

• Hazardous Substances Data: 57132-40-8(Hazardous Substances Data)

Upstream product

• 693-95-8 4-Methylthiazole 
• 99-73-0 para-bromophenacyl bromide 

Downstream Products

• 57132-31-7 Dimethyl 1-(p-bromophenyl)-1-hydroxy-4-methyl-1H-pyrrolo<2,1-c>-1,4-thiazine-7,8-dicarboxylate 
• 57132-39-5 1-(4-bromo-phenyl)-1-(cis-2-carboxy-vinyloxy)-4-methyl-1H-pyrrolo[2,1-c][1,4]thiazine-7-carboxylic acid 
• 57132-35-1 1-(4-bromo-phenyl)-1-(cis-2-ethoxycarbonyl-vinyloxy)-4-methyl-1H-pyrrolo[2,1-c][1,4]thiazine-7-carboxylic acid ethyl ester 
• 57132-52-2 3-[2-(4-bromo-phenyl)-2-oxo-1-phenylcarbamoyl-ethyl]-4-methyl-thiazolium betaine 

Relevant articles and documents

Method for treating fibrotic diseases or other indications IC

Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I:

Preventing and reversing advanced glycosylation endproducts

The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises a thiazolium compound capable of inhibiting, and to some extent reversing, the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.